Subscribe to RSS
DOI: 10.1055/s-2007-1009167
© Georg Thieme Verlag, Stuttgart · New York
Hypolipidemic Effect of Intravenous Pluronic L-81 in Fasted Rats Treated with Triton WR-1339: Possible Inhibition of Hepatic Lipoprotein Secretion
Publication History
1987
1988
Publication Date:
14 March 2008 (online)
Summary
Pluronic L-81 (L-81), a non-ionic hydrophobic surfactant, is a powerful inhibitor of the secretion of lipid-transporting chylomicrons from intestinal epithelial cells to lymph. Since the other major organ that secretes lipoproteins into the circulation is the liver, whose principal lipid secretory product is very low density lipoprotein (VLDL), we tested the hypothesis that L-81 will also inhibit hepatic lipid secretion. Rats were fasted so that they had little lipid input from the intestine. We then administered Triton WR-1339 (tyloxapol) intravenously to block peripheral utilization of VLDL, causing plasma lipids to rise rapidly. Some animals were also given L-81 intravenously to test whether the L-81 would retard the tyloxapol-induced rise in plasma lipids. Administration of tyloxapol alone (250 mg/kg) increased plasma triglyceride, phospholipid and cholesterol concentrations considerably. Simultaneous administration of a small dose of L-81 (6 mg/kg) markedly reduced the rise in plasma triglyceride, particularly in the first hour (by 45%). L-81 also diminished the rise in plasma phospholipid and cholesterol, but to a lesser extent (30%). In the fasting rat, most of the plasma triglyceride is in VLDL; therefore, L-81 probably acts by decreasing the secretion of hepatic VLDL. Thus, Pluronic L-81 may be a useful tool for examining the secretion and metabolism of hepatic lipoproteins, in particular, VLDL.
Key-Words
Plasma Triglyceride - Plasma Cholesterol - Plasma Phospholipid - Very Low Density Lipoprotein (VLDL) - Hepatic Lipid Secretion - Tyloxapol